Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

CDC Says 205 Cases of Meningitis in 14 States; 15 Dead

Possible Meningitis Infection Linked to Second Product, FDA Says
The New England Compounding Center based in Framingham, Massachusetts. Photographer: Jared Wickerham/Getty Images

Two hundred and five people in 14 states are infected with meningitis traced to contaminated steroid shots, which have left 15 people dead, the U.S. Centers for Disease Control and Prevention said today.

The outbreak has spread to a new state, New Hampshire, the CDC said in a statement on its website today. The other states are Florida, Idaho, Illinois, Indiana, Maryland, Michigan, Minnesota, New Jersey, North Carolina, Ohio, Tennessee, Texas and Virginia, the agency said.

Two days ago, U.S. regulators said about 14,000 people who received pain-relieving steroid shots may be at risk for meningitis. The infections are traced to vials from a Framingham, Massachusetts-based pharmacy that mixed the steroid and sold it to 75 hospitals and clinics in 23 states, the CDC said.

The company in question, New England Compounding Pharmacy Inc., was sued by a woman who received a steroid shot that was recalled because it was potentially contaminated with a fungus putting recipients at risk for meningitis.

Injections of the tainted steroid -- an epidural shot used to treat neck and back pain -- were given starting May 21, the Atlanta-based CDC said. Meningitis is an inflammation of the lining of the brain and spinal cord usually caused by a viral or bacterial infection.

Reuters yesterday reported that NECC sold medication without gaining individual proof of prescriptions, citing e-mails it obtained. More than a dozen e-mails also showed the company sought to win bulk orders from physicians, the news service said. The company declined to comment to Reuters.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.